International Ophthalmology

, Volume 19, Issue 2, pp 117–120 | Cite as

Pars planitis: epidemiology and clinical outcome in a large community hospital in Mexico city

  • Gabriela Ortega-Larrocea
  • Lourdes Arellanes-Garcia
Geographical ophthalmology


Medical records of 51 patients with a diagnosis of pars planitis (97 eyes) were reviewed. Based upon the severity of vitreous inflammation, in 34 eyes (35) the condition was classified as mild, in 38 (39) as moderate, and in 25 eyes (26) as severe. Vascular sheathing was present in 51 eyes (53), snowballs in 42 (43), snowbanks in 29 (30), cataract in 19 (20), cystoid macular edema in 26 (27), retinal detachment in 4 (4) and glaucoma in 3 (3) eyes. Treatment consisted of prednisone and periocular injections of deposteroids or immunosuppressive agents; 13 patients required surgery for retinal repair, glaucoma, vitreous opacities or cataract. After treatment the visual acuity improved in 58 of the eyes, did not change in 33, and worsened in 9.

Key words

intermediate uveitis pars planitis uveitis in childhood cystoid macular edema 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Henderly DE, Genstler AJ, Rao NA, Smith RE. Pars planitis. Trans Ophthalmol Soc U.K. 1986; 105: 227–32.Google Scholar
  2. 2.
    Schepens CL. L'inflammation de la region de l'ora serrata et ses sequelles. Bull Soc Franc Ophthalmol 1959; 73: 113–24.Google Scholar
  3. 3.
    Welch RB, Maumenee AE, Wahlen HE. Peripheral posterior segment inflammation, vitreous opacities, and edema of the posterior pole. Arch Ophthalmol 1960; 64: 540–9.Google Scholar
  4. 4.
    Dinning WJ. Intermediate uveitis: History, terminology, definition. Pars planitis: systemic disease associations. Dev Ophthalmol 1992; 23: 3–8.Google Scholar
  5. 5.
    Malinowski SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology 1993; 100: 818–25.Google Scholar
  6. 6.
    Forster DJ, Rao NA, Smith RE. Corticosteroids in the treatment of intermediate uveitis. Dev Ophthalmol 1992; 23: 163–70.Google Scholar
  7. 7.
    Althaus C, Sundmacher R. Intermediate uveitis. Epidemiology, age and sex distribution. Dev Ophthalmol 1992; 23: 9–14.Google Scholar
  8. 8.
    Henderly DE, Genstler AJ, Smith RE, Rao NA. Changing patterns of uveitis. Am J Ophthalmol 1987; 103: 131–6.Google Scholar
  9. 9.
    Eichenbaum JW, Friedman AH, Mamelok AE. A clinical and histopathological review of intermediate uveitis (‘pars planitis’). Bull NY Acad Med 1988; 64: 164–74.Google Scholar
  10. 10.
    Henderly DE, Haymond RS, Rao NA, Smith RE. The significance of the pars plana exudate in pars planitis. Am J Ophthalzmol 1987; 103: 669–71.Google Scholar
  11. 11.
    Wetzig RP, Chan CC, Nussenblatt RB, Palestine AG, Mazur DO, Mittal KK. Clinical and immunopathological studies of pars planitis in a family. Br J Ophthalmol 1988; 72: 5–10.Google Scholar
  12. 12.
    Malinowski SM, Pulido JS, Goeken NE, Brown CK, Folk JC. The association of HLA-B8, B51, DR2 and multiple sclerosis in pars planitis. Ophthalmology 1993; 100: 1199–1205.Google Scholar
  13. 13.
    Graham EM, Edelsten C. Intermediate uveitis and sarcoidosis. Dev Ophthalmol 1992; 23: 106–10.Google Scholar
  14. 14.
    Smith RE, Godfrey WA, Kimura SJ. Chronic cyclitis. I. Course and visual prognosis. Trans Am Acad Ophthalmol Otolaryngol 1973; 77: 760–8.Google Scholar
  15. 15.
    Kimura SJ, Hogan MJ. Chronic cyclitis. Arch Ophthalmol 1964; 71: 193–201.Google Scholar
  16. 16.
    Chester GH, Blach RK, Cleary PE. Inflammation in the region of the vitreous base. Pars planitis. Trans Ophthalmol Soc UK 1976; 96: 151–7.Google Scholar
  17. 17.
    Pruett RC, Brockhurst RJ, Letts NF. Fluorescein angiography of peripheral uveitis. Am J Ophthalmol 1974; 77: 448–53.Google Scholar
  18. 18.
    Schmidt F. Fluorescein angiography in intermediate uveitis. Dev Ophthalmol 1992; 23: 139–44.Google Scholar
  19. 19.
    Godfrey WA, Smith RE, Kimura SJ. Chronic cyclitis. Corticos-teriod therapy. Trans Am Ophthalmol Soc 1976; 74: 178–88.Google Scholar
  20. 20.
    Smith RE, Nozik RA. Uveitis: A clinical approach to diagnosis and managment. 2nd ed. Baltimore, Pa, Williams & Wilkins, 1989:63–8.Google Scholar
  21. 21.
    Rao NA, Forster DJ, Augsburger JJ. The Uvea: Uveitis and intraocular neoplasms. New York, NY, Gower, 1992; 6.1–6.4.Google Scholar
  22. 22.
    Kaufman AH, Foster CS. Cataract extraction in patients with pars planitis. Ophthalmology 1993; 100: 1210–7.Google Scholar
  23. 23.
    Nölle B, Eckardt C. Cellular phenotype of vitreous cells in intermediate uveitis. Dev Ophthalmol 1992; 23: 145–9.Google Scholar
  24. 24.
    Nussenblatt RB, Palestine AG. Ciclosporin (Sandimmum) therapy. Experience in the treatment of pars planitis and present therapeutic guidelines. Dev Ophthalmol 1992; 23: 177–84.Google Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • Gabriela Ortega-Larrocea
    • 1
  • Lourdes Arellanes-Garcia
    • 1
  1. 1.Department of UveitisAsociación para evitar la ceguera en México, ‘Luis Sanchez Bulnes Hospital’ and National University of MexicoMexico CityMexico
  2. 2.San Lucas CoyoacánMéxico

Personalised recommendations